Kairos Pharma Signs Term Sheet for Two Oncology Assets
Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma’s clinical portfolio to target multi-billion...
Category : Healthcare and Pharmaceutical
Sun Nuclear QADS 2026 Advances Radiation Therapy QA
Sun Nuclear, a Mirion Medical company, today opened the QA & Dosimetry Symposium (QADS), taking place over the next two days in Rome, Italy. The...
P4ML Joins Orphan Therapeutics Accelerator to Expand Access
P4ML’s Expertise in Genomic Patient Identification, Ties to Middle East Health Initiatives and Irish Biopharmaceutical Roots to be Utilized in Support of OTXL’s Mission & Programs ...
Foundation Fighting Blindness Hosts Webinar on Retinal Medicine
The event will feature presentations from leading experts in stem cell therapies, cellular imaging, and the latest clinical developments in the treatment of inherited retinal diseases and...
Illumina Drives Cancer Breakthroughs Using Multiomics Tools
At AGBT, researchers reveal new findings from studies leveraging Illumina’s multiomics solutions Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina’s...
Nexus Precision Health Acquires Leal Health to Scale Precision Med
Combined platform connects 250,000+ patients, 40,000+ clinicians, and 90+ biopharma partners—creating a real-world network for precision medicine execution and outcomes Nexus Precision Health (“Nexus”), a...
Argo Biopharma Shares Phase II Results for BW-20805 at AAAAI
-Poster Presentation Selected as Late Breaking Abstract- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, has been selected as...
CJ BIO Publishes Study on BiomeNrich POST SZ075 for Skin Health
CJ BIO announced the publication of clinical research findings on its postbiotic ingredient, BiomeNrich™ POST SZ075, in an international peer-reviewed journal. The study strengthens the...
Matricelf Reports 2025 Milestones, 2026 Spinal Implant Roadmap
Matricelf Ltd. (TASE: MTLF), a biotechnology company developing personalized regenerative therapies for spinal cord injury, today issued a shareholder update summarizing its 2025 achievements and...
Sarepta Launches ELEVIDYS Gene Therapy Commercially in Japan
– Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years – Company is eligible to receive...
Grove Biopharma Reports Preclinical Study on MYC and KRAS Degradation
– Study represents a significant advancement in Grove’s Bionic Biologics™ platform – Grove Biopharma, a private biotechnology company engineering protein-like polymers (PLPs) – a new...
FDA Grants Full Approval to Pfizer’s BRAFTOVI for Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed...
AdvanCell Shows TheraPb Phase 2 Design of ADVC001 in Prostate CA
— The trial uses a response-driven dosing strategy and extended treatment across three prostate cancer populations, supported by the favorable clinical, pharmacokinetic and dosimetry results...
HekaBio, Alpha Tau Medical Get Japan Approval for Tumor Therapy
Offering a New Option for Head and Neck Cancer Treatment HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device ‘Alpha DaRT...
Azafaros Publishes Preclinical Data of Nizubaglustat in GM2
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept...